Abstract：
OBJECTIVE: To compare the efficacy, outcomes, and complications of single session (SS-SRS) and multisession (MS-SRS) stereotactic radiosurgery in the treatment of intracranial meningiomas.
METHODS: Relevant articles were retrieved from PubMed, Scopus, Web of Science, and Cochrane. A systematic review and meta-analysis of treatment protocols and outcomes were conducted. After the selection process, 20 articles describing 1483 cases were included.
RESULTS: A total of 1303 patients who underwent SS-SRS and 180 patients who underwent MS-SRS for the management of their intracranial meningioma were reported in the included studies. SS-SRS and MS-SRS had comparable one-year (SS-SRS: 98% vs. MS-SRS: 100%, p > 0.99) and five-year (SS-SRS: 94% vs. MS-SRS: 93%, p = 0.71) tumor control rates. The groups also had comparable tumor volume reduction/tumor regression rates (SS-SRS: 44% vs. MS-SRS: 25%, p = 0.25), tumor volume stability rates (SS-SRS: 51% vs. MS-SRS: 75%, p = 0.12), and tumor progression rates (SS-SRS: 4% vs. MS-SRS: 4%, p = 0.89). SS-SRS and MS-SRS yielded similar complication rates (10.4% vs. 11.4%, p = 0.68) and comparable functional improvement rates (MS-SRS: 44% vs. SS-SRS: 36%, p = 0.57). However, MS-SRS was used for significantly larger tumor volumes (MS-SRS: 23.8 cm3 vs. SS-SRS: 6.1 cm3, p = 0.02).
CONCLUSIONS: SS-SRS and MS-SRS resulted in comparable tumor control, tumor volumetric change, and functional outcomes despite significant biases in selecting patients for SS- or MS-SRS.
METHODS: Relevant articles were retrieved from PubMed, Scopus, Web of Science, and Cochrane. A systematic review and meta-analysis of treatment protocols and outcomes were conducted. After the selection process, 20 articles describing 1483 cases were included.
RESULTS: A total of 1303 patients who underwent SS-SRS and 180 patients who underwent MS-SRS for the management of their intracranial meningioma were reported in the included studies. SS-SRS and MS-SRS had comparable one-year (SS-SRS: 98% vs. MS-SRS: 100%, p > 0.99) and five-year (SS-SRS: 94% vs. MS-SRS: 93%, p = 0.71) tumor control rates. The groups also had comparable tumor volume reduction/tumor regression rates (SS-SRS: 44% vs. MS-SRS: 25%, p = 0.25), tumor volume stability rates (SS-SRS: 51% vs. MS-SRS: 75%, p = 0.12), and tumor progression rates (SS-SRS: 4% vs. MS-SRS: 4%, p = 0.89). SS-SRS and MS-SRS yielded similar complication rates (10.4% vs. 11.4%, p = 0.68) and comparable functional improvement rates (MS-SRS: 44% vs. SS-SRS: 36%, p = 0.57). However, MS-SRS was used for significantly larger tumor volumes (MS-SRS: 23.8 cm3 vs. SS-SRS: 6.1 cm3, p = 0.02).
CONCLUSIONS: SS-SRS and MS-SRS resulted in comparable tumor control, tumor volumetric change, and functional outcomes despite significant biases in selecting patients for SS- or MS-SRS.
摘要：
目的：比较疗效，结果，以及单节（SS-SRS）和多节（MS-SRS）立体定向放射外科治疗颅内脑膜瘤的并发症。
方法：相关文章来自PubMed，Scopus,WebofScience,还有Cochrane.对治疗方案和结果进行系统评价和荟萃分析。在选择过程之后，包括20篇描述1483例病例的文章。
结果：纳入的研究共报告了1303例接受SS-SRS治疗的患者和180例接受MS-SRS治疗颅内脑膜瘤的患者。SS-SRS和MS-SRS具有相当的一年(SS-SRS：98%与MS-SRS:100%,p>0.99）和五年期（SS-SRS：94%与MS-SRS:93%,p=0.71)肿瘤控制率。两组的肿瘤体积减少/肿瘤消退率也相当(SS-SRS：44%vs.MS-SRS:25%,p=0.25),肿瘤体积稳定率（SS-SRS：51%vs.MS-SRS:75%,p=0.12),和肿瘤进展率（SS-SRS：4%vs.MS-SRS:4%,p=0.89）。SS-SRS和MS-SRS的并发症发生率相似(10.4%vs.11.4%,p=0.68）和可比的功能改善率（MS-SRS：44%vs.SS-SRS:36%,p=0.57）。然而,MS-SRS用于明显更大的肿瘤体积（MS-SRS：23.8cm3与SS-SRS:6.1cm3,p=0.02)。
结论：SS-SRS和MS-SRS导致相当的肿瘤对照，肿瘤体积变化，和功能结局，尽管在选择SS或MS-SRS患者方面存在显著偏差。
方法：相关文章来自PubMed，Scopus,WebofScience,还有Cochrane.对治疗方案和结果进行系统评价和荟萃分析。在选择过程之后，包括20篇描述1483例病例的文章。
结果：纳入的研究共报告了1303例接受SS-SRS治疗的患者和180例接受MS-SRS治疗颅内脑膜瘤的患者。SS-SRS和MS-SRS具有相当的一年(SS-SRS：98%与MS-SRS:100%,p>0.99）和五年期（SS-SRS：94%与MS-SRS:93%,p=0.71)肿瘤控制率。两组的肿瘤体积减少/肿瘤消退率也相当(SS-SRS：44%vs.MS-SRS:25%,p=0.25),肿瘤体积稳定率（SS-SRS：51%vs.MS-SRS:75%,p=0.12),和肿瘤进展率（SS-SRS：4%vs.MS-SRS:4%,p=0.89）。SS-SRS和MS-SRS的并发症发生率相似(10.4%vs.11.4%,p=0.68）和可比的功能改善率（MS-SRS：44%vs.SS-SRS:36%,p=0.57）。然而,MS-SRS用于明显更大的肿瘤体积（MS-SRS：23.8cm3与SS-SRS:6.1cm3,p=0.02)。
结论：SS-SRS和MS-SRS导致相当的肿瘤对照，肿瘤体积变化，和功能结局，尽管在选择SS或MS-SRS患者方面存在显著偏差。
